Losing Weight Yields No Cardio Gain for Some
Europe's CHMP Bounces Vivus' Weight Loss Drug
By Catherine Shaffer
Staff Writer
Staff Writer
Vivus Inc. will appeal a negative opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The committee recommended against approval of Qsiva (phentermine/topiramate) based on concerns about potential cardiovascular and central nervous system effects over long term use, and other safety issues.